#BIO22: Fire­side chat with Zachary Bren­nan and Ian Thomp­son

Zachary Bren­nan:

Hel­lo, and wel­come to to­day’s Fire­side Chat. I’m Zachary Bren­nan, se­nior ed­i­tor at End­points News and with me to­day is Ian Thomp­son, se­nior vice pres­i­dent of Am­gen.

To­day we’ll be dis­cussing the evo­lu­tion of the US biosim­i­lar space, which has seen not on­ly a slow start when we com­pare to our Eu­ro­pean coun­ter­parts, but al­so long de­lays be­tween when cer­tain biosim­i­lars win ap­proval and when they ac­tu­al­ly launch in the US mar­ket. So, first off I want­ed to start by wel­com­ing Ian and I al­so want­ed to hear his take on how he’s seen the mo­men­tum build­ing around the biosim­i­lar in­dus­try in re­cent years, and maybe why he thinks that is the case that has been build­ing more in re­cent years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.